China's first homegrown EGFR inhibitor to be provided free to some patients
This article was originally published in Scrip
Executive Summary
Zhejiang Beta Pharma has been making waves in China's pharma industry since last August when it launched Conmana (icotinib), the first patented, targeted small-molecule drug for non-small cell lung cancer (NSCLC) to be developed in the country.